Addressing the global threat of antibiotic resistance

News

VenatoRx Pharmaceuticals’ Christopher J. Burns, Ph.D. Named CEO of the Year by Life Sciences Pennsylvania
March 14, 2019
VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting
March 25, 2019
> See all News & Events

Pipeline

VenatoRx Team